We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Novavax Inc | NASDAQ:NVAX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.21 | -4.41% | 4.55 | 4.54 | 4.61 | 4.94 | 4.475 | 4.94 | 5,271,344 | 00:43:38 |
Conference details are as follows:
B. Riley FBR Annual Healthcare Conference | |
Title: | “Vaccine & Antibiotics Can’t Be Developed For Some Intractable Infectious Diseases” |
Date and Time: | Tuesday, September 4, 1:55 – 2:55 p.m. |
Moderator: | George Zavoico, B. Riley FBR |
Panelists: | Vivek Shinde, M.D., Ph.D., Director of Clinical Development, Novavax |
Robert Stein, M.D., Ph.D., Senior R&D Advisor, Agenus | |
Location: | New York Marriott East Side |
Citi 13th Annual Biotech Conference | |
Date: | Thursday, September 6 |
Forum: | Investor meetings |
Location: | Four Seasons Hotel Boston |
About Novavax
Novavax, Inc. (NASDAQ:NVAX) is a late-stage biotechnology company that drives improved health globally through the discovery and development of innovative vaccines to prevent serious respiratory diseases. ResVax, its RSV vaccine for infants via maternal immunization, is the only vaccine in a Phase 3 clinical program and is poised to help prevent the second leading cause of death in children under one year of age worldwide. Novavax is also advancing the clinical study of our influenza nanoparticle vaccine, which addresses key factors that lead to poor efficacy by currently approved flu vaccines. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic particles addressing urgent global health needs.
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Contact:
InvestorsNovavax, Inc.Erika TrahanSenior Manager, Investor & Public Relationsir@novavax.com240-268-2000
Westwicke PartnersJohn Woolfordjohn.woolford@westwicke.com443-213-0506
MediaSam BrownMike Beyermikebeyer@sambrown.com312-961-2502
1 Year Novavax Chart |
1 Month Novavax Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions